Lucid Diagnostics Inc.

In Q2 2026, Lucid Diagnostics performed 2,770 EsoGuard tests and recognized $1.5 million of revenue. Management said revenue was up about 17% from the prior quarter, while volume remained within the company’s target range of approximately 2,500 to 3,000 tests. On a cash basis, quarter-end cash was $33.4 million, unchanged from year-end, and the average burn over the last four quarters was $11.6 million per quarter, with Q2 burn at $11.3 million. The company also completed a common stock offering with net proceeds of about $16.8 million, and its $22 million secured convertible debt had a fair value of $23.5 million at quarter end. Forward-looking commentary focused on reimbursement and access rather than formal numeric guidance. Management said it remains confident a positive Medicare draft LCD is forthcoming, expects VA progress to contribute in the new federal fiscal year beginning October 1, and anticipates several additional Concert-adopting plans in coming months. They also said the pending cost-effectiveness model should be completed this summer and submitted for publication, with preliminary results already looking encouraging.

Dr. Lishan Aklog framed the quarter as one of steady commercialization progress while the company waits on Medicare. He highlighted the Concert coverage policy as a major validation of EsoGuard’s evidence base and said it should help with other laboratory benefit managers and regional plans. He also emphasized growing traction at the VA, health systems, and with healthcare economic evidence, describing all three as important building blocks for broader adoption.

Dennis McGrath focused on liquidity, burn, and revenue recognition. He said cash was $33.4 million at June 30, the company raised about $16.8 million net in a common stock offering, and burn averaged $11.6 million per quarter over the last four quarters, with Q2 at $11.3 million. He explained that recognized revenue of $1.5 million represented about 19% of the quarter’s roughly $7.6 million in pro forma test value at the list price of $2,749, and noted that only about 28% of adjudicated claims resulted in an allowable amount, with an average of $1,424 per test. He also said the company is increasing commercial headcount and programs, but argues the roughly $2,000 test price and 90% margin for the next patient should limit the incremental burn relative to many early-stage companies.

Analysts pressed management on Medicare timing, VA contribution, SG&A growth, and the significance of the first LBM policy. Management said the VA has not yet contributed meaningfully to volume because the business is still in the contracting and budget-cycle phase, but expects that to change as the new fiscal year begins October 1. On Medicare, management said it does not expect the personnel change at Palmetto GBA to alter its position and still believes the LCD is in late stages, with a possible backlog loosening at CMS. On Concert, management said the policy covers just under 10 million client-covered lives and that three plans have already adopted it, with more expected.